

Secondary Intelligence™

Safety issues account for about a quarter of the attrition in drug projects. If it is a result of the primary pharmacology, you have to either drop the target entirely or manage the risk. However, if this arises from off-target activity, you have the additional option to dial this out and avoid the associated adverse events (AEs). This is the discipline of Secondary Pharmacology, the focus of Certara's new in silico technology.


Secondary Intelligence uses off-target screening data to quantitatively predict safety outcomes in vivo and in the clinic?


SECONDARY INTELLIGENCE: PREDICTIVE TECHNOLOGY FOR IMPROVING SAFETY PROFILES

Secondary Intelligence™ assembles, curates and visualizes all secondary pharmacology analyses, providing key information on potential AEs, quantitatively rating each compound as to its likelihood of causing off-target safety issues that could impact clinical progress. The first module in Certara's ToxStudio™ integrated modelling & simulation platform for safety pharmacology, toxicology and patient safety, *Secondary Intelligence™* is the only tool available to address this translational challenge.


- Secondary Intelligence assembles curated, organised information for a compound's secondary pharmacology readouts and analysis in one place.
- It provides up-to-date literature-based information on the expected side effects of a given compound as it engages with a particular off-target receptor in clinical use.
- This data enables virtual in vitro in vivo extrapolation (IVIVE).
- It rates each compound with a 'low', 'intermediate' or 'high' likelihood of causing AEs at the off-target receptor in clinical use, based on quantitative analysis of clinically used drugs that specifically target that receptor, and on its predicted plasma Cmax

Like radar, Secondary Pharmacology provides early alerts and allows you to decide on your next move.





Secondary Intelligence software identifies the key safety/tox information about each receptor, allowing you to focus on how a test compound interacts with that receptor. It can address safety performance against multiple receptors. Secondary Intelligence ranks the likelihood of each off-target interaction during clinical use, color-coding in red, amber or green.



Secondary Intelligence prioritises “receptor interactions of concern” in a variety of data representations, and ranks compounds against each other to make quantitatively based decisions as to which compounds to progress.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

For more information visit www.certara.com or email sales@certara.com.